Treating hyperammonemia, reducing plasma ammonia with TLR4 antagonists
First Claim
Patent Images
1. A method for reducing plasma ammonia in a patient comprising administering to the patient an effective amount of an antagonist of TLR4, wherein the TLR4 antagonist comprises TAK-242 or STM28.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention derives from the finding that increased levels of Toll like receptor 4 (TLR4) is associated with liver failure and renal dysfunction and/or brain dysfunction and that by decreasing TLR4 levels in vivo, the kidney and brain consequences of liver disease that are precipitated by superimposed infection or inflammation may be reduced. Accordingly, the invention provides TLR4 antagonists for use in a method of treating an individual suffering from liver disease presenting with renal or brain dysfunction.
-
Citations
12 Claims
- 1. A method for reducing plasma ammonia in a patient comprising administering to the patient an effective amount of an antagonist of TLR4, wherein the TLR4 antagonist comprises TAK-242 or STM28.
- 7. A method of treating hyperammonemia in a patient comprising administering to said patient a therapeutically-effective amount of an antagonist of TLR4, wherein the TLR4 antagonist comprises TAK-242 or STM28.
Specification